Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400 Jackson Street, J312, Denver, CO 80206, USA.
Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400 Jackson Street, J310, Denver, CO 80206, USA.
Immunol Allergy Clin North Am. 2024 Nov;44(4):577-594. doi: 10.1016/j.iac.2024.08.001. Epub 2024 Sep 2.
Atopic dermatitis (AD) is a common chronic pruritic inflammatory skin disease that affects all ages and is recognized as a global health problem. Pathophysiology is complex with skin barrier abnormalities, immune dysregulation, and microbial dysbiosis all implicated. Markers of immune and inflammatory activation in the circulation provide a rationale for systemic therapy. Type 2 immune polarization is central, though other cytokine pathways including Th22 and Th17/IL-23 have been described, suggesting additional therapeutic targets in a subset of patients. Dupilumab and tralokinumab are monoclonal antibodies currently approved for moderate-to-severe AD with lebrikizumab and nemolizumab in late stages of development.
特应性皮炎（AD）是一种常见的慢性瘙痒性炎症性皮肤病，可影响所有年龄段人群，被认为是一个全球性的健康问题。其发病机制复杂，皮肤屏障异常、免疫失调和微生物失调均与之相关。循环中免疫和炎症激活的标志物为全身治疗提供了依据。2 型免疫极化是其核心机制，尽管已经描述了包括 Th22 和 Th17/IL-23 在内的其他细胞因子途径，这表明在一部分患者中存在其他潜在治疗靶点。度普利尤单抗和特利鲁单抗是目前已获批用于中重度 AD 的单克隆抗体，而 lebrikizumab 和 nemolizumab 处于研发后期阶段。
